Aclaris Therapeutics (ACRS) EBT Margin (2017 - 2026)
Aclaris Therapeutics' (ACRS) quarterly EBT Margin came in at 1876.8% in Q1 2026, down 60608.0% year-on-year from N/an in Q1 2025, and up 22.39% quarter-over-quarter from 2418.38% in Q4 2025.
Aclaris Therapeutics (ACRS) EBT Margin (2017 - 2026) Analysis & Trends
Aclaris Therapeutics' EBT Margin history runs 10 years deep, the most recent figure standing at 1876.8% for Q1 2026.
- On a quarterly basis, EBT Margin fell 60608.0% year-over-year to 1876.8% in Q1 2026; TTM through Mar 2026 was 1276.87%, a 44491.0% decrease from a year earlier, with the FY2025 full-year figure at 3488.03%, down 278255.0% from the prior year.
- EBT Margin rose to 1876.8% in Q1 2026 per ACRS's latest filing, from 2418.38% in the prior quarter.
- Across five years, EBT Margin topped out at 10.65% in Q4 2023 and bottomed at 2749.89% in Q4 2022.
- The 5-year median for EBT Margin is 1175.66% (2024), against an average of 1247.79%.
- Across the five-year window, EBT Margin surged 957130 bps in 2022 and slumped 124272 bps in 2025, its largest moves.
- Year by year, EBT Margin stood at 2749.89% in 2022, then jumped by 100 bps to 10.65% in 2023, then plunged by 10934 bps to 1175.66% in 2024, then sank by 106 bps to 2418.38% in 2025, then climbed by 22 bps to 1876.8% in 2026.
- Per Business Quant, the three latest ACRS EBT Margin figures stand at 1876.8% (Q1 2026), 2418.38% (Q4 2025), and 581.72% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Aclaris Therapeutics | 705.88 Mn | 705.88 Mn | 1.60 Mn | -1,876.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,876.80% |
| Dec 31, 2025 | -2,418.38% |
| Sep 30, 2025 | -581.72% |
| Jun 30, 2025 | -1,061.68% |
| Mar 31, 2025 | -1,270.72% |
| Dec 31, 2024 | -1,175.66% |
| Sep 30, 2024 | -222.32% |
| Jun 30, 2024 | -414.50% |
| Mar 31, 2024 | -726.77% |
| Dec 31, 2023 | -10.65% |
| Sep 30, 2023 | -354.89% |
| Jun 30, 2023 | -2,086.57% |
| Mar 31, 2023 | -1,349.60% |
| Dec 31, 2022 | -2,749.89% |
| Sep 30, 2022 | -191.34% |
| Jun 30, 2022 | -2,105.04% |
| Mar 31, 2022 | -2,615.97% |
| Dec 31, 2021 | -12,321.19% |
| Sep 30, 2021 | -2,317.06% |
| Jun 30, 2021 | -1,947.48% |